Coverage for the indication versus for the drug posts 61–80

I had written a reply contradicting post #59 and deleted it. Here is what survived.

The confident answers on coverage and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.

Confirming post #59 from a second method, which matters more than confirming it from a second person.

Nothing here is legal or medical advice, and appeal processes differ enough by jurisdiction and payer that specifics do not transfer.

Where coverage was granted, saying what the successful submission contained is one of the more useful posts on the site.

It is worth stating the boring hypothesis before the interesting one.

Adding a note of thanks rather than an opinion. I did not know most of that.

Coming back to post #63, because the follow-up matters more than the original answer.

Reimbursement changes: a compound covered one year might not be the next. A formulary decision in January can change by April. Checking again before refilling saves frustration.

Small correction to my own earlier position on coverage. I had the units the wrong way round, which changes the conclusion by an order of magnitude and therefore changes it entirely.

Worth separating coverage as a question about the compound from coverage as a question about the documentation. They get answered by different people and only one of them is answerable here.

This follows post #67 rather than contradicting it.

Keep every document with dates in one place. An appeal months later is assembled from whatever you kept.

That distinction has done more work for me than anything else in this category.

Nothing to add, except that this is the answer I would give if asked.

I disagree with the framing of coverage above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.

The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.

Coverage for weight management versus diabetes: many formularies cover these compounds for type 2 diabetes but not for weight management. The indication matters and appeals based on the covered indication work better.

Checked the coverage claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope.

Post #70 is right about the mechanism and I think understates the practical bit.

The honest answer on coverage is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.

Most people get the first two right and then argue about the fourth.

Same experience here, different supplier, so it is at least not unique to one of them.